PL3016682T3 - Sposoby leczenia nowotworu - Google Patents

Sposoby leczenia nowotworu

Info

Publication number
PL3016682T3
PL3016682T3 PL14741936T PL14741936T PL3016682T3 PL 3016682 T3 PL3016682 T3 PL 3016682T3 PL 14741936 T PL14741936 T PL 14741936T PL 14741936 T PL14741936 T PL 14741936T PL 3016682 T3 PL3016682 T3 PL 3016682T3
Authority
PL
Poland
Prior art keywords
methods
treating cancer
cancer
treating
Prior art date
Application number
PL14741936T
Other languages
English (en)
Inventor
Henning Walczak
Silvia VON KARSTEDT
Original Assignee
Ucl Business Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ucl Business Ltd filed Critical Ucl Business Ltd
Publication of PL3016682T3 publication Critical patent/PL3016682T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
PL14741936T 2013-07-05 2014-07-03 Sposoby leczenia nowotworu PL3016682T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1312155.3A GB201312155D0 (en) 2013-07-05 2013-07-05 Therapeutic invention
PCT/GB2014/052025 WO2015001345A1 (en) 2013-07-05 2014-07-03 Methods for treating cancer
EP14741936.0A EP3016682B1 (en) 2013-07-05 2014-07-03 Methods for treating cancer

Publications (1)

Publication Number Publication Date
PL3016682T3 true PL3016682T3 (pl) 2020-08-10

Family

ID=49033439

Family Applications (1)

Application Number Title Priority Date Filing Date
PL14741936T PL3016682T3 (pl) 2013-07-05 2014-07-03 Sposoby leczenia nowotworu

Country Status (10)

Country Link
US (1) US10093716B2 (pl)
EP (1) EP3016682B1 (pl)
DK (1) DK3016682T3 (pl)
ES (1) ES2791624T3 (pl)
GB (1) GB201312155D0 (pl)
HU (1) HUE048625T2 (pl)
LT (1) LT3016682T (pl)
PL (1) PL3016682T3 (pl)
PT (1) PT3016682T (pl)
WO (1) WO2015001345A1 (pl)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3024474T3 (da) 2013-07-23 2022-03-28 Serenity Pharmaceuticals Llc Sammensætninger omfattende desmopressin i kombination med en beta-3-adrenoreceptor-agonist
JP6864990B2 (ja) 2015-04-16 2021-04-28 日東電工株式会社 Ｂｒａｆ遺伝子変異を有する細胞に対する細胞死誘導剤、当該細胞の増殖抑制剤及び当該細胞の増殖異常に起因する疾患の治療用医薬組成物
CN116271056A (zh) * 2015-04-16 2023-06-23 日东电工株式会社 针对具有braf基因突变的细胞的细胞死亡诱导试剂、该细胞的增殖抑制试剂及用于治疗由该细胞的增殖异常导致的疾病的医药组合物
GB202016058D0 (en) 2020-10-09 2020-11-25 Ucl Business Ltd Therapeautic treatment

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7528239B1 (en) 1997-02-13 2009-05-05 Immunex Corporation Receptor that binds trail
US6072047A (en) 1997-02-13 2000-06-06 Immunex Corporation Receptor that binds trail
WO2002094880A1 (en) * 2001-05-18 2002-11-28 Kirin Beer Kabushiki Kaisha Anti-trail-r antibodies

Also Published As

Publication number Publication date
HUE048625T2 (hu) 2020-08-28
US20160297865A1 (en) 2016-10-13
GB201312155D0 (en) 2013-08-21
DK3016682T3 (da) 2020-05-18
LT3016682T (lt) 2020-05-25
ES2791624T3 (es) 2020-11-05
WO2015001345A1 (en) 2015-01-08
PT3016682T (pt) 2020-05-20
US10093716B2 (en) 2018-10-09
EP3016682A1 (en) 2016-05-11
EP3016682B1 (en) 2020-02-19

Similar Documents

Publication Publication Date Title
IL292193A (en) Anti-b7–h1 antibodies for the treatment of tumors
IL245731A0 (en) Combined treatment for cancer
HK1220155A1 (zh) 治療癌症的方法
IL245281A0 (en) Methods and preparations for the treatment of cancer
SG11201603050TA (en) Methods for treating cancers
EP2968343A4 (en) POLY THERAPY FOR TREATING CANCER
GB201322725D0 (en) Cancer therapy
GB201318983D0 (en) Radiotherapy apparatus
IL244353A0 (en) Compounds and use for cancer treatment
HK1220900A1 (zh) 癌症的治療
HK1213817A1 (zh) 治療癌症的方法
GB201308325D0 (en) Cancer Therapy
HK1215164A1 (zh) 處理方法
AP2015008803A0 (en) Methods for treating psoriasis using an anti-il-23antibody
PL3054959T3 (pl) Sposoby leczenia złośliwych nowotworów zwłóknieniowych
IL245037B (en) Treatment for pancreatic cancer
HK1219513A1 (zh) 治療癌症的方法
EP2986120A4 (en) METHYLTRANSFERASE HEMMER FOR THE TREATMENT OF CANCER
HK1223547A1 (zh) 癌症治療方法
EP2961412A4 (en) CANCER THERAPY
PT3016682T (pt) Métodos para tratamento do cancro
PL3071192T3 (pl) Związek kurkufenol do zastosowania w leczeniu nowotworu
EP2941270A4 (en) METHODS FOR TREATING INFLAMMATION
EP2968390A4 (en) INJECTABLE FORMULATIONS FOR THE TREATMENT OF CANCER
EP2971044A4 (en) COMPOSITIONS AND METHOD FOR THE TREATMENT OF CANCER